Featured News

New research indicates that a specific set of natural memory T cells, when triggered by gluten, rapidly become destructive and cause intestinal damage in celiac disease patients.

iCureCeliac® is the Foundation’s patient-powered tool that is the single best resource for celiac disease researchers around the world helping to accelerate the search for treatments and a cure.

Last week in Washington, D.C., the Celiac Disease Foundation and our allies secured two critical wins in our mission to drive policy change to improve the health of those living with celiac disease.

New research studying the association of celiac disease and inflammatory bowel disease (IBD) shows a strong relationship between the two conditions.

Curing Celiac: A Short Story, a new film by Hayley Repton, encourages patients to join the iCureCeliac® patient registry, the single best patient-centered resource for celiac disease researchers in the world.

On July 27, Celiac Disease Foundation CEO, Marilyn G. Geller, will be presenting the “Role of Patient Advocacy in Clinical Trials” on a webinar hosted by the Society for the Study of Celiac Disease.

An analysis by an independent statistician of the ongoing Phase 3 trial for Larazotide has concluded that a substantial number of new patients would have to be added to the existing trial in order to get scientifically meaningful results.

Last week, the Celiac Disease Foundation, as part of The Defense Health Research Consortium, co-signed a letter requesting a budget increase for the Congressionally Directed Medical Research Programs.

Celiac Disease Foundation Chief Executive, Marilyn G. Geller, was recently interviewed by The Waiting Room, a patient information website, to highlight the work and accomplishments of the Foundation.

Researchers found that roughly one-third of celiac patients reported using probiotics for perceived health benefits, despite the lack of evidence that probiotics are an effective treatment for celiac disease symptoms.